Bio-Rad Laboratories BIO Clinical Diagnostics — Depreciation, Depletion and Amortization

Other segment segments

Similar metrics at other companies

PRGFour — Depreciation, Depletion and Amortization

$253K-35.5%

APDEurope — Depreciation, Depletion and Amortization

$72.5M+27.6%

NFGUtility — Depreciation, Depletion and Amortization

$18.09M+0.8%

CNXShale — Depreciation, Depletion and Amortization

$112.96M+6.2%

TRSPackaging — Depreciation, Depletion and Amortization

$8.79M+5.5%

DINOMarketing — Depreciation, Depletion and Amortization

$8M+14.3%

FAQ

What is Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization?

Bio-Rad Laboratories (BIO) reported clinical diagnostics — depreciation, depletion and amortization of $22.6M in Q1 2026.

How has Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization changed year-over-year?

Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization increased by 7.1% year-over-year, from $21.1M to $22.6M.

What is the long-term trend for Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization?

Over 4 years (2021 to 2025), Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization has grown at a 2.2% compound annual growth rate (CAGR), from $82.8M to $90.4M.

What does clinical diagnostics — depreciation, depletion and amortization mean?

The non-cash expense allocated to the Clinical Diagnostics segment for the wear and tear of tangible assets and the amortization of intangible assets over their useful lives. This reflects the consumption of capital investments.